QBIO: High-Growth Biotech with Big Catalysts Set to Drive the Action

Date : May 4, 2020

New Opportunity:  Q BioMed Inc. (OTCMKTS:QBIO)

 

  • Strong FDA-approved non-opioid cancer treatment heading to market now
  • Developing powerful vascular adjunct treatments to help improve health outcomes for infectious disease cases, including flu and COVID-19
  • On the verge of a Nasdaq uplist
  • Small float and bullish breakout posture

 

The Coronavirus has cast a bright spotlight on emerging growth opportunities in the healthcare sector. Investment capital is chasing the dream: non-cyclical demand curve with high growth potential.

Q BioMed (QBIO) offers exactly that type of potential opportunity.

The company is on the cusp of genuine commercial-stage activity in both the rare disease and oncology spaces. It’s principle leading asset (Strontium89) is an FDA-approved breakthrough non-opioid pain treatment for those suffering from bone pain related to metastatic cancer.

New regulations are coming down to the pike – fast! – for opioid painkillers. And Q BioMed is the only producer of Strontium89 in the western world.

As QBIO goes into full commercialization of Strontium89, it would be surprising to see anything other than a sharp burst in terms of market share given the pale cast on opiates now, and increasingly.

In addition, the company is working on adjunct treatments for complications stemming from COVID-19. The main asset under development (rapid path) through the company’s partner, Mannin, is targeting the stabilization of ‘leaky vessels’ that play a critical part in organ injury, a major determinant of negative outcomes in patients affected by several infectious diseases, including influenza and the current COVID-19 pandemic.

As we have seen with the stories around Gilead (GILD) and remdesivir of late, treatments that can improve outcomes are of enormous interest.

We would also note that the company is explicitly setting up for an uplist onto the Nasdaq exchange.

The float is tight and the technical picture is extremely promising. A tie-in to the coronavirus and imminent commercial activity suggest analyst research that recently put a $5/share target on QBIO shares may even be undershooting the mark.

 

Symbol:  QBIO
Company:  Q BioMed Inc.
Quote:  http://finance.yahoo.com/q?s=QBIO
Latest News: 
http://finance.yahoo.com/q/h?s=QBIO+Headlines

qbio, QBIO: High-Growth Biotech with Big Catalysts Set to Drive the Action

Who is QBIO

qbio, QBIO: High-Growth Biotech with Big Catalysts Set to Drive the Action

Q BioMed Inc. (OTCMKTS:QBIO) is a biomedical acceleration and development company that focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies.

The company’s ace offering is Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies. Q BioMed Inc. has a research partnership with Mannin Research Inc. for the development of therapeutics to treat a variety of vascular diseases, including the new coronavirus.

Q BioMed Inc. is a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

qbio, QBIO: High-Growth Biotech with Big Catalysts Set to Drive the Action

The company focuses exclusively in the biotechnology and healthcare sectors, targeting a broad spectrum of biomedical products and healthcare solutions. Q’s expertise is in business & product development and the capital formation required for phased advancement of products.

Q BioMed’s team assists companies by utilizing its strategic partners and network of experts to provide public market access for private company assets. 80% of biomedical start-ups lack capital and resources to transition from incubation to development and beyond.

The company expects to maximize risk-adjusted returns by focusing on value-driven assets from early stage to near-revenue businesses where the technical, regulatory, and commercial risks have been mitigated or where major valuation inflections are imminent.

Recent Catalysts

The company recently announced that, together with its technology partner, Mannin Research, they are accelerating the rapid development of novel drugs for the treatment of life-threatening complications caused by COVID-19 and other viral infections.

According to the release, this novel drug program is being evaluated by government programs for funding and accelerated development under various COVID-19 response initiatives. Q BioMed and Mannin hope to have at least one treatment in human trials this year. The accelerated development is the result of a joint venture (JV) between Mannin, with its Tie2 based small molecule platform that addresses vascular leakage, and Cyclica, a Toronto, Canada based biotechnology company that has a proprietary AI-augmented drug discovery platform, Ligand Design and Ligand Express. The JV agreement will deploy Cyclica’s unique AI platform to accelerate the development of new treatments based on Mannin’s Tie2 based platform.

Given the bright covid-19 spotlight now dominating the market landscape, the fact that the company has a tangible and credible path to market for something that can potentially help in this fight is huge news. But it’s even more important because

Just before that, the company announced the appointment of Kristin Keller to the newly created position of Chief Commercial Officer.

That’s the type of title we like to see, and it confirms the thesis that 2020 is when this company makes the leap to commercial-stage operations with real top-line growth just around the corner.

qbio, QBIO: High-Growth Biotech with Big Catalysts Set to Drive the Action
qbio, QBIO: High-Growth Biotech with Big Catalysts Set to Drive the Action
qbio, QBIO: High-Growth Biotech with Big Catalysts Set to Drive the Action

According to that release, Kristin will be focused on driving the global commercialization of Q BioMed’s lead product, the FDA approved, non-opioid Strontium89  (Strontium Chloride Sr-89 Injection, USP). She will also contribute strategic insight and direction to the Company’s portfolio of earlier stage assets. For more than 20 years, Keller has been working with global pharmaceutical, biotechnology and medical device companies as a marketer and strategist. She has deep experience in the specialty and orphan drug space and has worked for biotech companies including Actelion, Raptor, Alexion and Biomarin, as well as larger pharmaceutical companies including Novartis, Sanofi, AstraZeneca and Roche.

In other words, she’s a ringer.

And most importantly, in mid-February, the company announced the launch of its FDA approved non-opioid drug Strontium89 (Strontium Chloride Sr-89 Injection, USP), which has been shown in clinical studies to help relieve persistent pain associated with cancer that has metastasized to bone.

As noted there, in several multicenter, placebo-controlled trials in cancer patients with persistent pain after external beam radiation therapy for bone metastases, pain relief occurred in more patients treated with a single injection of Strontium89 than in patients treated with an injection of placebo, with a greater percentage of patients experiencing pain scores of zero without any need for opioid or non-opioid rescue analgesics. Duration of pain palliation has been shown to range from 2 to 5 months in most patients. Strontium89 can be redosed every 90 days.

This is huge because an estimated 10 million people are living with bone metastases.

As the company notes, due to the opioid crisis, clinicians and patients are looking for pain management alternatives. Strontium89, which is administered every 3 months, has been shown to relieve pain in over 70% of patients who received the treatment.

Another major catalyst here lying in wait, besides the onset of topline growth, is the company’s plan to uplist to the Nasdaq in the very near term.

Technical Analysis

With a float of just 18.6 million shares, QBIO is trading on a stick of dynamite. We have seen this explosive character several times in the past few months. This stock can take off like a rocket. On three separate occasions, we have seen QBIO shares leap by 50-100% in less than a week in the past 6 months.

Right now, we are seeing a “bullish flag pattern” following the burst to the upside that hit toward the end of March. That sprint has been consolidated in a healthy manner at this point, and a follow-through move to the upside could be primed.

qbio, QBIO: High-Growth Biotech with Big Catalysts Set to Drive the Action

About QBIO

qbio, QBIO: High-Growth Biotech with Big Catalysts Set to Drive the Action

About QBIO

QBIO (Q BioMed Inc.) is a biomedical acceleration and development company that focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies.

The company’s ace offering is Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies. Q BioMed Inc. has a research partnership with Mannin Research Inc. for the development of therapeutics to treat a variety of vascular diseases, including the new coronavirus.

Q BioMed Inc. is a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

Key Points:

  • QBIO is moving into commercial-stage for its FDA-approved cancer drug, Strontium89.. ie, here comes the payoff
  • QBIO has a small trading float of just 18.6M, which suggests the stock could launch higher on any additional influx of interest.
  • QBIO is also developing a key potential treatment for COVID-19 and other infectious diseases, including influenza
  • QBIO is coming off an RSI trough under 30 in mid-March, pointing to a massively oversold stock now heading back the other way, and consolidating in a nice “Bullish Flag” breakout pattern
  • QBIO is planning on uplisting to the Nasdaq, which is often a major bull catalyst for OTC stocks
qbio, QBIO: High-Growth Biotech with Big Catalysts Set to Drive the Action

Conclusion

QBIO is sitting in a very strong posture on the chart, with a tight float in play. That creates the potential for a big squeezing pop to the upside on new strong catalysts – which is something that looks plentiful over the near-term ahead.

The company is moving to aggressively commercialize its FDA-approved cancer treatment and hold a leadership position in the non-opioid cancer treatment marketplace, which is likely to grow as more and more opioid legislation hits the books.

Q BioMed is also in the process of rapidly developing and commercializing drugs in the adjunct treatment market for infectious diseases, like COVID-19 and influenza.

qbio, QBIO: High-Growth Biotech with Big Catalysts Set to Drive the Action

We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for marketing purposes only. Dailytrendingstocks engaged in the business of marketing and advertising companies. All content on our website is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. Neither the owner of Our Newsletter nor any of its members, officers, directors, contractors or employees are licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. Dailytrendingstocks owns no shares of any of the companies mentioned here within, nor intends to buy any in the future.

Free WordPress Themes, Free Android Games